Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.
- Carl Icahn has seized a stake in BMS as rumours of an acquisition swirl
- Zykadia, a lung cancer drug from Novartis, has been granted Priority Review by the FDA
- Minoryx has received Orphan Drug Designation from the FDA as well as the EMA for its lead candidate, MIN-102, for neurodegenerative disease
- A patient has died in Roche‘s hemophilia trial for ACE910 but an investigator concluded the drug was not responsible
- Researchers at the Leibniz Institute on Aging have characterised a mechanism of gene inactivation that may prevent aging and cancer
- Bacteria have been engineered to convert carbon dioxide into methane by researchers at the University of Kent
- Memorial Sloan Kettering Cancer Center has shown that using CRISPR to engineer CAR-T cells gives them “better stamina” than TALEN-engineered cells.
- The British Medical Journal has published an article warning of the negative impact of the Trump presidency across the Atlantic
- Germany is about to allow the sale of GMOs without labelling
Snoop Dogg or Real Dog?
Images from ChrisVanLennepPhoto, Curioso, Eric Gevaert and Pranisa Thanatattanon / shutterstock.com